Search
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
MGC030
go.drugbank.com/drugs/DB33973ExperimentalMGC030 is a biologic drug. MGC030 is under investigation in clinical trial NCT07822399 (A Study of MGC030 in Participants With Advanced Solid Tumors).
BMS-791826
go.drugbank.com/drugs/DB15023InvestigationalBMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
Zonampanel anhydrous
go.drugbank.com/drugs/DB20448InvestigationalZonampanel anhydrous is under investigation in clinical trial NCT00044070 (A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients). … Zonampanel anhydrous is a small molecule drug.
SW033291
go.drugbank.com/drugs/DB32765Experimental[A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474] … SW033291 is a small molecule 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor.
Ancitabine
go.drugbank.com/drugs/DB20595ExperimentalThe usage of the INN stem '-citabine' in the name indicates that Ancitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative. … Ancitabine is a small molecule drug.
Galocitabine
go.drugbank.com/drugs/DB21373ExperimentalThe usage of the INN stem '-citabine' in the name indicates that Galocitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative. … Galocitabine is a small molecule drug.
Tasurgratinib
go.drugbank.com/drugs/DB21222InvestigationalTasurgratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. … Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)). Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.
Abivertinib
go.drugbank.com/drugs/DB15327InvestigationalThe study is expected to be completed in March 2021.[L17398] … [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies.